Athersys

Athersys Financing Cash Flow

Delisted

The Net Financing Cash Flow of Athersys (ATHX) as of Nov 20, 2026 is 11.63 M USD. In the previous year, Net Financing Cash Flow was 30.84 M USD — a change of -62.30% (lower).

Financing Cash Flow

11.63 MUSD

YoY

-62.30%

Last updated:

Net Financing Cash Flow of Athersys is 2023 11.63 M USD. Net Financing Cash Flow of Athersys was 2022 30.84 M USD. It decreases by -62.30% lower compared to the previous year.

The Athersys Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2016
3.72 M USD
Jan 1, 2017
38.87 M USD
Jan 1, 2018
36.01 M USD
Jan 1, 2019
19.89 M USD
Jan 1, 2020
79.48 M USD
Jan 1, 2021
63.41 M USD
Jan 1, 2022
30.84 M USD
Jan 1, 2023
11.63 M USD
The Athersys Financing Cash Flow history
YEARFinancing Cash FlowYoY
11.63 MUSD-62.30%
30.84 MUSD-51.36%
63.41 MUSD-20.22%
79.48 MUSD+299.64%
19.89 MUSD-44.77%
36.01 MUSD-7.35%
38.87 MUSD+943.66%
3.72 MUSD-65.51%
10.80 MUSD-46.73%
20.27 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Athersys Stock analysis

What does Athersys do? Athersys Inc. is a biopharmaceutical company based in Cleveland, Ohio. It was founded in 1995 and focuses on the discovery, development, and commercialization of regenerative therapies and cell therapies. The idea for founding Athersys Inc. came from the vision that stem cell therapies could change the way we treat diseases. In the early stages of the company, the team focused on isolating and characterizing human stem cells. Over time, the research evolved and Athersys Inc. shifted its focus to developing drugs that promote tissue and organ regeneration. Athersys Inc.'s business model involves developing stem cell-based medications that are tested in clinical trials. The goal is to combat diseases such as stroke, heart attack, inflammatory diseases, and respiratory syndromes. Athersys Inc. utilizes a proprietary technology platform called MultiStem to isolate, expand, and differentiate stem cells. The company works closely with clinical partners in the pharmaceutical and biotech industry to conduct clinical trials and bring medications to market. Athersys has four divisions: Hematology, Neurology, Pulmonology, and Cardiology. In hematology, Athersys focuses on developing a therapy for cancer treatment. By administering MultiStem, a type of stem cell therapy, they hope to reduce the side effects of chemotherapy and kill cancer cells. In neurology, Athersys focuses on developing medications for the treatment of strokes and neurological disorders. The goal is to trigger regenerative processes in the brain and promote the growth of nerve cells and the regeneration of brain tissue. In pulmonology, Athersys focuses on developing therapies for the treatment of lung diseases such as ARDS and COPD. In cardiology, Athersys aims to improve the healing process after a heart attack by supporting the natural regeneration process of the heart muscle. Athersys' products are still in development and are in various stages of clinical trials. The most well-known product of Athersys is the MultiStem product. The company utilizes its proprietary technology platform to isolate and expand stem cells from human bone marrow and adipose tissue. MultiStem is intended to promote tissue regeneration and reduce inflammation. It has been tested in various preclinical and clinical trials and has shown promising results. Overall, Athersys Inc. is a company that focuses on regenerative therapies and cell therapies. By utilizing its proprietary technology platform MultiStem, Athersys hopes to develop stem cell-based therapies that can contribute to the cure of many different diseases. Although the company is still in the development and study phase, Athersys has already made impressive progress and remains an important player in the biopharmaceutical industry. Athersys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athersys stock

Net Financing Cash Flow of Athersys is 11.63 M USD in 2023.

Net Financing Cash Flow of Athersys changed from 30.84 M USD to 11.63 M USD, representing a -62.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Athersys since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Athersys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Athersys

All Key Metrics — Athersys